Suvecaltamide

Suvecaltamide (MK-8998) is a selective T-type calcium channel inhibitor with oral efficacy. Suvecaltamide exhibits no cytotoxicity in myeloma cell lines and does not affect the antitumor efficacy of Bortezomib (BTZ) . Suvecaltamide reverses BTZ-induced peripheral neuropathy (CIPN) in mouse and rat models, and helps inhibit myeloma growth[1].

Product Specifications

CAS Number

[953778-58-0]

Product Name Alternative

MK-8998; CX-8998; JZP385

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Calcium Channel

Type

Reference compound

Related Pathways

Membrane Transporter/Ion Channel; Neuronal Signaling

Applications

Neuroscience-Neuromodulation

Field of Research

Cancer; Neurological Disease

Assay Protocol

https://www.medchemexpress.com/MK-8998.html

Concentration

10mM

Purity

99.96

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=C(N[C@@H](C1=NC=C(OCC(F)(F)F)C=C1)C)CC2=CC=C(C(C)C)C=C2

Molecular Formula

C20H23F3N2O2

Molecular Weight

380.40

Precautions

H302, H315, H319, H335

References & Citations

[1]Cristina Meregalli, et al. Reversal of Bortezomib-Induced Neurotoxicity by Suvecaltamide, a Selective T-Type Ca-Channel Modulator, in Preclinical Models. Cancers (Basel) . 2021 Oct 7;13 (19) :5013.